• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    89Bio Inc (NQ: ETNB )

    9.290 +0.150 (+1.64%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about 89Bio Inc

    < Previous 1 2 3 4 5 Next >
    Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
    Via Investor's Business Daily
    ETNB Stock Earnings: 89bio Beats EPS for Q2 2024
    ETNB stock results show that 89bio beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
    Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
    Via Benzinga
    Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
    Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
    Via Investor's Business Daily
    The Week Ahead: What's Next
    The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
    Via Talk Markets
    ETNB Stock Earnings: 89bio Misses EPS for Q1 2024
    ETNB stock results show that 89bio missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Analyst Ratings for 89bio
    Via Benzinga
    Analyst Expectations for 89bio's Future
    Via Benzinga
    Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
    Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
    Via The Motley Fool
    Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
    Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
    Via Benzinga
    Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
    Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning! 
    Via InvestorPlace
    Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
    Via Benzinga
    Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
    The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
    Via Investor's Business Daily
    Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
    89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
    89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in  
    Via Benzinga
    Exposures Product Safety
    89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
    89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with  
    Via Benzinga
    Why Shares of 89bio Plummeted on Tuesday
    So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors. 
    Via The Motley Fool
    Akero Therapeutics' Disappointing NASH Data Drags Its Rival
    Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to  
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
    Via Benzinga
    Why Akero Therapeutics Stock Is Crashing Today
    Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX). 
    Via The Motley Fool
    PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
    U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    US Stocks Gain; PepsiCo Posts Upbeat Earnings
    U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
    Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.